CytoSorbents links with Biocon for sepis therapy in emerging markets
This article was originally published in Scrip
Executive Summary
Biocon is to distribute CytoSorbents' sepsis therapy, CytoSorb, in India and certain other emerging markets in a strategic partnership under which India's largest biotechnology company will have exclusive commercialization rights to the product in the territories.